FDG-PET/CT Accurate in Diagnosing Breast Cancer Recurrence

Share this content:
FDG-PET/computed tomography with dual-time-point imaging was accurate in diagnosing breast cancer recurrence.
FDG-PET/computed tomography with dual-time-point imaging was accurate in diagnosing breast cancer recurrence.

[18F]fluorodeoxyglucose (FDG)-positron emission tomography (PET)/computed tomography (CT) with dual-time-point imaging was accurate in diagnosing breast cancer recurrence with only a small number of false-positive cases, a study published in the Journal of Clinical Oncology has shown.1

For the study, researchers sought to investigate diagnostic accuracy of FDG-PET/CT, contrast-enhanced CT, and bone scintigraphy in patients with suspected breast cancer recurrence.

Researchers prospectively evaluated 100 women with suspected recurrence of breast cancer. Each woman underwent 1-hour and 3-hour FDG-PET/CT, contrast-enhanced CT, and bone scintigraphy within approximately 10 days. Imaging results were compared with the reference standard of biopsy results along with treatment decisions and clinical follow-up.

Researchers found that FDG-PET/CT imaging resulted in no false negatives and fewer false positives than contrast-enhanced CT and bone scintigraphy, and accuracy of results were similar between the 2 time points.

For distant recurrence, the area under the receiver operating curve was 0.99 (95% CI, 0.97 - 1) for FDG-PET/CT, 0.84 (95% CI, 0.73 - 0.94) for contrast-enhanced CT, and 0.86 (95% CI, 0.77 - 0.94) for the combined contrast-enhanced CT and bone scintigraphy. The area under the receiver operating curve represents the accuracy of a particular test. An area under the receiver operating curve of 0.90 to 1 is typically considered to have excellent accuracy, while 0.80 to 0.90 represent good accuracy.

Results also showed that 22% of the 100 patients were confirmed to have distant recurrence, of which 18 had bone involvement. Nineteen patients had local recurrence only.

RELATED: 21-gene Recurrence Score Predicts Survival in Stage 4 Breast Cancer

Further, exploratory analyses demonstrated that FDG-PET/CT had better diagnostic accuracy than contrast-enhanced CT alone or contrast-enhanced CT combined with bone scintigraphy in diagnosing distant, bone, and local recurrence.

Reference

  1. Hildebrandt MG, Gerke O, Baun C, et al. [18F]Fluorodeoxyglucose (FDG)-positron emission tomography (PET)/computed tomography (CT) in suspected recurrent breast cancer: a prospective comparative study of dual-time-point FDG-PET/CT, contrast-enhanced CT, and bone scintigraphy [published online ahead of print March 21, 2016]. J Clin Oncol. doi: 10.1200/JCO.2015.63.5185.

Related Resources

You must be a registered member of Cancer Therapy Advisor to post a comment.

Regimen and Drug Listings

GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION

Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Prostate Cancer Regimens Drugs
Rare Cancers Regimens
Renal Cell Carcinoma Regimens Drugs
Skin Cancer Regimens Drugs
Urologic Cancers Regimens Drugs

Sign Up for Free e-newsletters